Advertisement

Pharmacy World and Science

, Volume 21, Issue 5, pp 239–240 | Cite as

Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN

  • Catherijne A.J. Knibbe
  • Victorine S. Koster
  • Leon P.H.J. Aarts
  • Han J.M. Langemeijer
  • Meindert Danhof
Article

Abstract

In a pilot study on the first application of Propofol 6% SAZN in humans, the pharmacokinetics and safety of the new product seem to be similar to those of Propofol 1% SAZN and Diprivan®‐10 after bolus injection. The results will have to be confirmed in a larger clinical study in order to develop Propofol 6% SAZN as an alternative for Diprivan®‐10.

anaesthesia Clinical pharmacology Emulsion formulation Fat emulsion Propofol Pharmacokinetics 

References

  1. 1.
    Bryson HM, Fulton BR, Faulds D. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 1995;50:513-59.PubMedGoogle Scholar
  2. 2.
    Fulton B, Sorkin EM. Propofol. An overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs 1995;50:636-57.PubMedGoogle Scholar
  3. 3.
    Gottardis M, Khünl-Brady KS, Koller W, Sigl G, Hackl JM. Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth 1989;62:393-6.PubMedGoogle Scholar
  4. 4.
    Parke TJ, Stevens JE, Rice ASC, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 1992;305:613-6.PubMedGoogle Scholar
  5. 5.
    Knibbe CAJ, Koster VS, Deneer VHM, Stuurman RM, Kuks PFM, Lange R. Determination of propofol in low volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1998;706:305-10.PubMedGoogle Scholar
  6. 6.
    Cummings GC, Dixon J, Kay NH, et al. Dose requirements of ICI 35,868 (Propofol, 'Diprivan') in a new formulation for induction of anaesthesia. Anaesthesia 1984;39:1168-71.PubMedGoogle Scholar
  7. 7.
    Dutta S, Matsumoto Y, Ebling WF. Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation. J Pharm Sci 1997;86:967-9.PubMedGoogle Scholar
  8. 8.
    Dutta S, Ebling WF. Emulsion formulation reduces propofol dose requirements and enhances safety. Anesthesiology 1997;87:1394-405.PubMedGoogle Scholar
  9. 9.
    Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. Anesth Analg 1997;85:1399-403.PubMedGoogle Scholar
  10. 10.
    Cox EH, Knibbe CAJ, Koster VS, et al. Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. Pharm Res 1998;15:442-8.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Catherijne A.J. Knibbe
  • Victorine S. Koster
  • Leon P.H.J. Aarts
  • Han J.M. Langemeijer
  • Meindert Danhof

There are no affiliations available

Personalised recommendations